Face up to prostate problems
Ypozane® is a novel, non-invasive oral treatment containing osaterone acetate for Benign Prostate Hyperplasia in dogs – a condition which affects over 80% of entire dogs over the age of five
Prostate Hyperplasia is often difficult to diagnose until the disease has progressed to a marked increase of the size of the prostate gland. The simple, once-daily, seven-day treatment has been shown to reduce prostate volume by 40% in just 14 days and show prolonged benefits for up to six months.
Product Features & Benefits:
Available in four tablet strengths suitable for dogs weighing 3kg to 60kg
Simple effective course - given orally, with or without food, at 0.25 to 0.5mg/kg once daily for seven days
Conveniently packaged in packs of seven tablets: one box for one complete treatment course
Fast-acting, with 40% reduction of prostate volume within 2 weeks, and with the effects sustained for up to six months1
Use medicines responsibly. www.noah.co.uk/responsible.
Further information is available on the SPC or on request from Virbac Ltd.
Ypozane contains osaterone acetate which is an androgen receptor antagonist which blocks the action of testosterone on prostatic tissue. It is approved for the treatment of benign prostatic hypertrophy (BPH) in male dogs.
The pack of Ypozane contains seven tablets and the dose is one tablet, with or without food, once daily for 7 days. The effect of the treatment course can last at least 5 months.
3 to 7.5 kg = 1.875 mg tablet
7.5 to 15 kg = 3.75 mg tablet
15 to 30 kg = 7.5 mg tablet
30 to 60 kg = 15 mg tablet
Clinical improvement including reduction in size of the prostate should be evident within 14 days with studies showing between 41% and 46% reduction at this point.
No. Serum testosterone and testicular function is not significantly altered by the use of Ypozane. Dogs will remain fertile and can be used for stud whilst under treatment for Ypozane.
No. There are no benefits from using Ypozane for behavioural problems.